Expanded rare disease footprint Mirum has a commercial portfolio spanning Alagille syndrome, PFIC, bile-acid synthesis disorders, and CTX, with a late-stage pipeline including volixibat for PSC and PBC, brelovitug for HDV, and MRM-3379 for Fragile X. This presents cross-selling opportunities across specialized hepatology, pediatric rare diseases, and neurology-focused accounts, as well as potential indications for expansion into related cholestatic conditions.

Recent FDA activity The company recently secured FDA engagement with a package acceptance for zilurgisertib and an action date targeted for September, signaling regulatory momentum and potential near-term launches. This creates short to mid-term sales opportunities around payer discussions, launch readiness, and neurology/hepatic clinics awaiting new therapies.

Strong 2026 momentum Q1 2026 revenue was $159.9 million with full-year net product sales guidance raised to $660–$680 million, indicating robust performance and growing commercial footprint. This momentum supports increasing field coverage, expanded KOL engagement, and more aggressive market access initiatives in specialty channels.

Clinical expansion opportunities Expansion program EXPAND targets additional rare cholestatic diseases beyond ALGS and PFIC, offering a pipeline-led growth narrative for accounts seeking innovative solutions for patients with limited options. Partnerships or co-promotion discussions around EXPAND candidates could unlock early access collaborations and channel partnerships.

Strategic partnerships potential With a global footprint, patient-community focus, and a history of collaboration across the rare disease ecosystem, Mirum is well-positioned to engage specialty pharmacies, patient advocacy groups, and academic centers for joint patient access programs, real-world evidence generation, and companion diagnostic initiatives to accelerate adoption and reimbursement.